FDA Grants Accelerated Approval to Zongertinib for HER2-Mutated NSCLC

On February 26, the U.S. Food and Drug Administration granted accelerated approval to Zongertinib (brand name Hernexeos) for adults with HER2-mutated unresectable or metastatic nonsquamous Non‑Small Cell Lung Cancer. The mutation must be identified using an FDA-authorized diagnostic test.

This approval allows the drug to be used as an initial targeted therapy for patients whose tumors carry HER2 mutations, offering a new treatment option earlier in the course of the disease.

Building on an Earlier FDA Approval

The latest authorization expands on a previous accelerated approval granted in August 2025, when the medication was approved for patients whose cancer had already progressed after prior systemic treatment.

Both approvals were supported by results from the Beamion LUNG‑1 Trial, which investigated the effectiveness and safety of the drug in patients with HER2-mutated lung cancer.

According to John V. Heymach, the coordinating investigator of the trial and chair of thoracic/head and neck medical oncology at MD Anderson Cancer Center, the therapy represents an important advancement.

He noted that zongertinib offers strong clinical activity, manageable side effects, and the convenience of once-daily oral dosing, making it a promising targeted treatment for patients with HER2-driven lung cancer.

Clinical Trial Results

The FDA evaluated outcomes from 72 patients in the Beamion LUNG-1 study who had HER2-mutated advanced nonsquamous NSCLC and had not yet received systemic therapy.

Key results included:

  • Objective Response Rate (ORR): 76%

  • 64% of responding patients maintained their response for at least six months

  • 44% experienced responses lasting one year or longer

These findings indicate that the treatment can produce meaningful and durable tumor responses in many patients.

Safety and Side Effects

Treatment-related side effects led to dose discontinuation in about 6% of patients.

Across a larger safety group of 292 patients, including both previously treated and untreated individuals, the most frequently reported side effects included:

  • Diarrhea (54%)

  • Skin rash (27%)

  • Liver toxicity (26%)

  • Fatigue (25%)

  • Nausea (23%)

  • Musculoskeletal pain (21%)

  • Upper respiratory infections (20%)

The prescribing information also includes warnings for potential risks such as:

  • Liver damage (hepatotoxicity)

  • Left ventricular dysfunction

  • Interstitial Lung Disease or pneumonitis

  • Embryo-fetal toxicity

Patients receiving the drug require monitoring for these potential complications.

Expert Perspectives

Early findings from the Beamion LUNG-1 trial were presented at the American Association for Cancer Research Annual Meeting 2025.

During the meeting, Charles M. Rudin, deputy director of Memorial Sloan Kettering Cancer Center, emphasized that an effective oral therapy for HER2-driven lung cancer had long been needed.

He noted that zongertinib appears to meet the key expectations for this type of targeted treatment.

Ongoing Research

Researchers are continuing to evaluate the drug in larger studies.

Two major trials are currently underway:

  • Beamion LUNG-2: A phase 3 study testing zongertinib as a first-line treatment for HER2-mutated NSCLC

  • Beamion LUNG-3: A phase 3 trial studying the drug as adjuvant therapy after surgery in patients with early-stage HER2-mutated NSCLC

These trials will help confirm the drug’s long-term effectiveness and may support full regulatory approval in the future.

Recommended Dosage

The FDA recommends dosing based on body weight:

  • 120 mg once daily for patients weighing under 198 pounds (90 kg)

  • 180 mg once daily for patients weighing 198 pounds or more

The medication can be taken with or without food and is typically continued until the disease progresses or side effects become unacceptable.

A New Targeted Option for HER2-Mutated Lung Cancer

HER2 mutations occur in a small but significant portion of lung cancer patients and have historically lacked effective targeted treatments. The accelerated approval of zongertinib introduces a new therapy designed specifically for this genetic subtype.

As ongoing trials continue to evaluate its benefits, the drug may represent an important step forward in precision medicine for lung cancer, giving patients access to more personalized and potentially effective treatment options.